Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study
- Authors
- Kang, Hye Jin; Kim, Won Seog; Kim, Seok Jin; Lee, Je-Jung; Yang, Deok-Hwan; Kim, Jin Seok; Lee, Se-Ryeon; Lee, Gyeong-Won; Kim, Hyo Jung; Kim, Ho Young; Oh, Sung Yong; Kim, Hugh Chul; Eom, Hyeon-Seok; Chung, Jooseop; Park, Jinny; Suh, Cheolwon; Ryoo, Baek-Yeol
- Issue Date
- Apr-2012
- Publisher
- SPRINGER
- Keywords
- CVP; First-line; Immunochemotherapy; Marginal zone lymphoma; Rituximab
- Citation
- ANNALS OF HEMATOLOGY, v.91, no.4, pp.543 - 551
- Journal Title
- ANNALS OF HEMATOLOGY
- Volume
- 91
- Number
- 4
- Start Page
- 543
- End Page
- 551
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16477
- DOI
- 10.1007/s00277-011-1337-6
- ISSN
- 0939-5555
- Abstract
- We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2) and vincristine 1.4 mg/m(2) (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16477)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.